No data to show
XNAS
CLYM
Market cap91mUSD
Jun 10, Last price
1.37USD
Name
Eliem Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-74m
L+110.42%
CFO
-16m
L-24.45%
Profile
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 30,361 | 50,153 | 45,135 | |||
Unusual Expense (Income) | ||||||
NOPBT | (30,361) | (50,153) | (45,135) | |||
NOPBT Margin | ||||||
Operating Taxes | (21) | 109 | ||||
Tax Rate | ||||||
NOPAT | (30,361) | (50,132) | (45,244) | |||
Net income | (73,897) 110.42% | (35,119) -22.57% | (45,353) -4.48% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 119,750 | 841 | ||||
BB yield | -1.15% | |||||
| Debt | ||||||
Debt current | 157 | 668 | 300 | |||
Long-term debt | 907 | 45 | 660 | |||
Deferred revenue | ||||||
Other long-term liabilities | 7 | |||||
Net debt | (211,465) | (106,085) | (122,606) | |||
| Cash flow | ||||||
Cash from operating activities | (15,562) | (20,599) | (37,369) | |||
CAPEX | ||||||
Cash from investing activities | (121,092) | 68,981 | 34,440 | |||
Cash from financing activities | 130,729 | 841 | ||||
FCF | (29,294) | (46,188) | (45,004) | |||
| Balance | ||||||
Cash | 150,919 | 106,798 | 123,566 | |||
Long term investments | 61,610 | |||||
Excess cash | 212,529 | 106,798 | 123,566 | |||
Stockholders' equity | (229,846) | (155,978) | (121,215) | |||
Invested Capital | 442,259 | 264,348 | 250,410 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 26,987 | 26,312 | ||||
Price | 1.80 -33.33% | 2.70 -26.43% | 3.67 -64.91% | |||
Market cap | 72,865 -24.54% | 96,563 -64.81% | ||||
EV | (33,220) | (26,043) | ||||
EBITDA | (30,361) | (50,153) | (45,135) | |||
EV/EBITDA | 0.66 | 0.58 | ||||
Interest | 1,593 | |||||
Interest/NOPBT | ||||||